NYSE:VAPO

Vapotherm Competitors

$23.03
-0.05 (-0.22 %)
(As of 04/14/2021 12:51 PM ET)
Add
Compare
Today's Range
$22.75
Now: $23.03
$23.48
50-Day Range
$21.80
MA: $24.44
$28.00
52-Week Range
$16.86
Now: $23.03
$54.42
Volume5,074 shs
Average Volume359,808 shs
Market Capitalization$594.34 million
P/E RatioN/A
Dividend YieldN/A
Beta-1.5

Competitors

Vapotherm (NYSE:VAPO) Vs. INO, GNMK, LMNX, SILK, ATEC, and LUNG

Should you be buying VAPO stock or one of its competitors? Companies in the industry of "surgical & medical instruments" are considered alternatives and competitors to Vapotherm, including Inovio Pharmaceuticals (INO), GenMark Diagnostics (GNMK), Luminex (LMNX), Silk Road Medical (SILK), Alphatec (ATEC), and Pulmonx (LUNG).

Inovio Pharmaceuticals (NASDAQ:INO) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, earnings and profitability.

Volatility and Risk

Inovio Pharmaceuticals has a beta of 1.08, indicating that its share price is 8% more volatile than the S&P 500. Comparatively, Vapotherm has a beta of -1.5, indicating that its share price is 250% less volatile than the S&P 500.

Earnings and Valuation

This table compares Inovio Pharmaceuticals and Vapotherm's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Inovio Pharmaceuticals$4.11 million461.72$-119,360,000.00($1.16)-7.85
Vapotherm$48.10 million12.36$-51,060,000.00($2.74)-8.41

Vapotherm has higher revenue and earnings than Inovio Pharmaceuticals. Vapotherm is trading at a lower price-to-earnings ratio than Inovio Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Inovio Pharmaceuticals and Vapotherm, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Inovio Pharmaceuticals14302.25
Vapotherm00303.00

Inovio Pharmaceuticals presently has a consensus price target of $17.00, suggesting a potential upside of 87.22%. Vapotherm has a consensus price target of $43.00, suggesting a potential upside of 89.01%. Given Vapotherm's stronger consensus rating and higher probable upside, analysts clearly believe Vapotherm is more favorable than Inovio Pharmaceuticals.

Profitability

This table compares Inovio Pharmaceuticals and Vapotherm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Inovio Pharmaceuticals-8,518.10%-78.17%-40.33%
Vapotherm-47.80%-51.59%-29.83%

Insider and Institutional Ownership

36.0% of Inovio Pharmaceuticals shares are owned by institutional investors. Comparatively, 70.4% of Vapotherm shares are owned by institutional investors. 4.0% of Inovio Pharmaceuticals shares are owned by insiders. Comparatively, 34.4% of Vapotherm shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Summary

Vapotherm beats Inovio Pharmaceuticals on 9 of the 13 factors compared between the two stocks.

GenMark Diagnostics (NASDAQ:GNMK) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, profitability, analyst recommendations, institutional ownership and risk.

Profitability

This table compares GenMark Diagnostics and Vapotherm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
GenMark Diagnostics-16.95%-39.36%-13.02%
Vapotherm-47.80%-51.59%-29.83%

Analyst Ratings

This is a breakdown of current ratings for GenMark Diagnostics and Vapotherm, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
GenMark Diagnostics05002.00
Vapotherm00303.00

GenMark Diagnostics presently has a consensus price target of $22.0125, suggesting a potential downside of 8.24%. Vapotherm has a consensus price target of $43.00, suggesting a potential upside of 89.01%. Given Vapotherm's stronger consensus rating and higher probable upside, analysts clearly believe Vapotherm is more favorable than GenMark Diagnostics.

Earnings & Valuation

This table compares GenMark Diagnostics and Vapotherm's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
GenMark Diagnostics$88.02 million19.92$-47,350,000.00($0.82)-29.26
Vapotherm$48.10 million12.36$-51,060,000.00($2.74)-8.41

GenMark Diagnostics has higher revenue and earnings than Vapotherm. GenMark Diagnostics is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

96.9% of GenMark Diagnostics shares are held by institutional investors. Comparatively, 70.4% of Vapotherm shares are held by institutional investors. 3.3% of GenMark Diagnostics shares are held by insiders. Comparatively, 34.4% of Vapotherm shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk and Volatility

GenMark Diagnostics has a beta of 3.02, suggesting that its share price is 202% more volatile than the S&P 500. Comparatively, Vapotherm has a beta of -1.5, suggesting that its share price is 250% less volatile than the S&P 500.

Summary

GenMark Diagnostics beats Vapotherm on 9 of the 14 factors compared between the two stocks.

Luminex (NASDAQ:LMNX) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, risk, dividends, earnings, analyst recommendations, institutional ownership and profitability.

Valuation and Earnings

This table compares Luminex and Vapotherm's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Luminex$334.64 million5.21$-3,840,000.00($0.21)-175.48
Vapotherm$48.10 million12.36$-51,060,000.00($2.74)-8.41

Luminex has higher revenue and earnings than Vapotherm. Luminex is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Luminex and Vapotherm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Luminex4.60%3.75%2.73%
Vapotherm-47.80%-51.59%-29.83%

Volatility and Risk

Luminex has a beta of 0.61, meaning that its share price is 39% less volatile than the S&P 500. Comparatively, Vapotherm has a beta of -1.5, meaning that its share price is 250% less volatile than the S&P 500.

Institutional and Insider Ownership

88.1% of Luminex shares are held by institutional investors. Comparatively, 70.4% of Vapotherm shares are held by institutional investors. 9.4% of Luminex shares are held by insiders. Comparatively, 34.4% of Vapotherm shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Luminex and Vapotherm, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Luminex03002.00
Vapotherm00303.00

Luminex presently has a consensus price target of $37.00, suggesting a potential upside of 0.38%. Vapotherm has a consensus price target of $43.00, suggesting a potential upside of 89.01%. Given Vapotherm's stronger consensus rating and higher probable upside, analysts clearly believe Vapotherm is more favorable than Luminex.

Summary

Luminex beats Vapotherm on 9 of the 14 factors compared between the two stocks.

Vapotherm (NYSE:VAPO) and Silk Road Medical (NASDAQ:SILK) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, risk, valuation, earnings and dividends.

Institutional and Insider Ownership

70.4% of Vapotherm shares are owned by institutional investors. 34.4% of Vapotherm shares are owned by insiders. Comparatively, 7.8% of Silk Road Medical shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Volatility & Risk

Vapotherm has a beta of -1.5, meaning that its stock price is 250% less volatile than the S&P 500. Comparatively, Silk Road Medical has a beta of 1.41, meaning that its stock price is 41% more volatile than the S&P 500.

Earnings & Valuation

This table compares Vapotherm and Silk Road Medical's top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vapotherm$48.10 million12.36$-51,060,000.00($2.74)-8.41
Silk Road Medical$63.35 million27.84$-52,420,000.00($1.36)-37.74

Vapotherm has higher earnings, but lower revenue than Silk Road Medical. Silk Road Medical is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vapotherm and Silk Road Medical's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vapotherm-47.80%-51.59%-29.83%
Silk Road Medical-53.66%-40.79%-24.56%

Analyst Recommendations

This is a summary of current ratings and price targets for Vapotherm and Silk Road Medical, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vapotherm00303.00
Silk Road Medical02202.50

Vapotherm currently has a consensus price target of $43.00, indicating a potential upside of 89.01%. Silk Road Medical has a consensus price target of $61.75, indicating a potential upside of 20.32%. Given Vapotherm's stronger consensus rating and higher possible upside, analysts clearly believe Vapotherm is more favorable than Silk Road Medical.

Summary

Vapotherm beats Silk Road Medical on 8 of the 14 factors compared between the two stocks.

Vapotherm (NYSE:VAPO) and Alphatec (NASDAQ:ATEC) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, institutional ownership, risk and analyst recommendations.

Valuation & Earnings

This table compares Vapotherm and Alphatec's revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Vapotherm$48.10 million12.36$-51,060,000.00($2.74)-8.41
Alphatec$113.43 million14.40$-57,000,000.00($1.09)-15.75

Vapotherm has higher earnings, but lower revenue than Alphatec. Alphatec is trading at a lower price-to-earnings ratio than Vapotherm, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Vapotherm and Alphatec's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Vapotherm-47.80%-51.59%-29.83%
Alphatec-51.95%-266.45%-40.80%

Volatility and Risk

Vapotherm has a beta of -1.5, suggesting that its stock price is 250% less volatile than the S&P 500. Comparatively, Alphatec has a beta of 1.53, suggesting that its stock price is 53% more volatile than the S&P 500.

Analyst Ratings

This is a summary of current ratings and target prices for Vapotherm and Alphatec, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Vapotherm00303.00
Alphatec00703.00

Vapotherm presently has a consensus price target of $43.00, indicating a potential upside of 89.01%. Alphatec has a consensus price target of $15.4286, indicating a potential downside of 10.04%. Given Vapotherm's higher probable upside, research analysts plainly believe Vapotherm is more favorable than Alphatec.

Insider & Institutional Ownership

70.4% of Vapotherm shares are held by institutional investors. Comparatively, 31.8% of Alphatec shares are held by institutional investors. 34.4% of Vapotherm shares are held by insiders. Comparatively, 28.2% of Alphatec shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Vapotherm beats Alphatec on 8 of the 13 factors compared between the two stocks.

Pulmonx (NASDAQ:LUNG) and Vapotherm (NYSE:VAPO) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their institutional ownership, profitability, valuation, analyst recommendations, dividends, earnings and risk.

Earnings and Valuation

This table compares Pulmonx and Vapotherm's gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Pulmonx$32.60 million48.06$-20,700,000.00N/AN/A
Vapotherm$48.10 million12.36$-51,060,000.00($2.74)-8.41

Pulmonx has higher earnings, but lower revenue than Vapotherm.

Institutional & Insider Ownership

70.4% of Vapotherm shares are held by institutional investors. 34.4% of Vapotherm shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Profitability

This table compares Pulmonx and Vapotherm's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
PulmonxN/AN/AN/A
Vapotherm-47.80%-51.59%-29.83%

Analyst Recommendations

This is a breakdown of recent recommendations and price targets for Pulmonx and Vapotherm, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Pulmonx03502.63
Vapotherm00303.00

Pulmonx presently has a consensus price target of $58.00, suggesting a potential upside of 32.12%. Vapotherm has a consensus price target of $43.00, suggesting a potential upside of 89.01%. Given Vapotherm's stronger consensus rating and higher probable upside, analysts plainly believe Vapotherm is more favorable than Pulmonx.

Summary

Pulmonx beats Vapotherm on 6 of the 11 factors compared between the two stocks.


Vapotherm Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Inovio Pharmaceuticals logo
INO
Inovio Pharmaceuticals
1.4$9.11-4.2%$1.82 billion$4.11 million-6.70
GenMark Diagnostics logo
GNMK
GenMark Diagnostics
1.5$23.99-0.0%$1.75 billion$88.02 million-58.51Increase in Short Interest
Luminex logo
LMNX
Luminex
1.5$36.85-0.3%$1.75 billion$334.64 million94.49Analyst Upgrade
Unusual Options Activity
News Coverage
Silk Road Medical logo
SILK
Silk Road Medical
1.1$51.32-2.6%$1.72 billion$63.35 million-42.07
Alphatec logo
ATEC
Alphatec
0.8$17.17-0.2%$1.63 billion$113.43 million-15.61Insider Selling
Pulmonx logo
LUNG
Pulmonx
1.4$43.90-2.5%$1.61 billion$32.60 million0.00Increase in Short Interest
Cardiovascular Systems logo
CSII
Cardiovascular Systems
1.7$37.75-3.3%$1.47 billion$236.54 million-57.20
MiMedx Group logo
MDXG
MiMedx Group
1.7$12.22-1.5%$1.38 billion$299.26 million-13.00
Atrion logo
ATRI
Atrion
1.1$648.60-0.5%$1.18 billion$155.07 million36.54
Tactile Systems Technology logo
TCMD
Tactile Systems Technology
1.2$56.48-2.2%$1.08 billion$189.49 million-125.51
SI-BONE logo
SIBN
SI-BONE
1.2$33.16-0.6%$1.08 billion$67.30 million-20.72Increase in Short Interest
Cerus logo
CERS
Cerus
1.5$6.36-1.6%$1.05 billion$74.65 million-16.31News Coverage
LeMaitre Vascular logo
LMAT
LeMaitre Vascular
1.9$49.65-0.7%$1.03 billion$117.23 million53.39
OrthoPediatrics logo
KIDS
OrthoPediatrics
1.5$49.60-1.1%$964.42 million$72.55 million-34.44
AngioDynamics logo
ANGO
AngioDynamics
1.4$23.98-0.2%$916.43 million$264.16 million-5.36Decrease in Short Interest
CryoLife logo
CRY
CryoLife
1.8$22.67-0.5%$891.15 million$276.22 million-59.66
Orthofix Medical logo
OFIX
Orthofix Medical
1.2$43.16-0.7%$847.99 million$459.95 million35.97
Surmodics logo
SRDX
Surmodics
1.3$56.96-0.9%$790.83 million$94.86 million712.00
OraSure Technologies logo
OSUR
OraSure Technologies
1.7$10.34-0.2%$742.48 million$154.60 million-44.96
Antares Pharma logo
ATRS
Antares Pharma
1.8$4.03-0.2%$679.37 million$123.86 million67.18
Intersect ENT logo
XENT
Intersect ENT
1.4$19.94-1.0%$652.07 million$109.14 million-10.44
SeaSpine logo
SPNE
SeaSpine
1.3$21.55-2.0%$589.95 million$159.08 million-12.90Analyst Upgrade
Anika Therapeutics logo
ANIK
Anika Therapeutics
1.5$41.06-1.6%$579.22 million$114.51 million-87.36Gap Down
Pulse Biosciences logo
PLSE
Pulse Biosciences
1.5$22.01-3.0%$556.70 millionN/A-9.70
Accuray logo
ARAY
Accuray
2.3$5.26-0.8%$484.93 million$382.93 million37.57News Coverage
iCAD logo
ICAD
iCAD
1.5$18.52-2.3%$451.02 million$31.34 million-19.49
AVITA Medical logo
RCEL
AVITA Medical
1.5$20.88-0.6%$449.02 million$14.26 million-10.09Analyst Report
Increase in Short Interest
ClearPoint Neuro logo
CLPT
ClearPoint Neuro
1.4$20.91-3.8%$415.73 million$11.22 million-47.52News Coverage
Profound Medical logo
PROF
Profound Medical
1.6$20.20-1.2%$414.73 million$4.17 million-17.26News Coverage
Cytosorbents logo
CTSO
Cytosorbents
1.7$9.05-2.2%$400.19 million$24.95 million-27.42
PAVmed logo
PAVM
PAVmed
1.4$4.97-4.2%$392.51 millionN/A-6.54Gap Down
UFP Technologies logo
UFPT
UFP Technologies
1.3$49.50-0.4%$370.59 million$198.38 million24.75
Acutus Medical logo
AFIB
Acutus Medical
1.3$13.29-0.9%$370.01 million$2.84 million0.00News Coverage
Soliton logo
SOLY
Soliton
1.1$17.49-4.9%$352.56 millionN/A-23.32
Neuronetics logo
STIM
Neuronetics
1.5$13.15-3.3%$322.94 million$62.66 million-7.83
Apyx Medical logo
APYX
Apyx Medical
1.0$9.51-1.4%$321.90 million$28.15 million-20.23Gap Down
Utah Medical Products logo
UTMD
Utah Medical Products
0.9$88.57-1.5%$317.93 million$46.90 million27.94
IRadimed logo
IRMD
IRadimed
1.5$23.94-2.2%$301.25 million$38.52 million74.81News Coverage
Gap Up
DarioHealth logo
DRIO
DarioHealth
1.3$18.59-0.1%$285.89 million$7.56 million-2.32
Co-Diagnostics logo
CODX
Co-Diagnostics
1.6$9.75-2.2%$273.47 million$220,000.0012.04
T2 Biosystems logo
TTOO
T2 Biosystems
1.4$1.40-1.4%$204.92 million$8.34 million-2.03
TELA Bio logo
TELA
TELA Bio
2.1$13.90-2.2%$200.72 million$15.45 million-4.78
Titan Medical logo
TMDI
Titan Medical
1.2$1.73-1.7%$186.19 millionN/A173.00Analyst Report
PolyPid logo
PYPD
PolyPid
1.4$9.57-2.9%$163.13 millionN/A0.00Analyst Upgrade
Decrease in Short Interest
News Coverage
Repro Med Systems logo
KRMD
Repro Med Systems
2.0$3.31-1.5%$144.99 million$23.16 million-331.00
Lyra Therapeutics logo
LYRA
Lyra Therapeutics
1.6$11.26-2.0%$142.82 millionN/A0.00
Apollo Endosurgery logo
APEN
Apollo Endosurgery
1.9$5.47-1.5%$140.05 million$50.71 million-4.41Decrease in Short Interest
NMRD
Nemaura Medical
0.2$6.19-1.5%$139.87 millionN/A-30.95Increase in Short Interest
News Coverage
Avinger logo
AVGR
Avinger
1.4$1.34-0.0%$127.70 million$9.13 million-1.02Decrease in Short Interest
Gap Up
Venus Concept logo
VERO
Venus Concept
1.9$2.11-1.9%$111.72 million$110.41 million-0.63News Coverage
Gap Down
This page was last updated on 4/14/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.